Duration of immunosuppressive therapy in autoimmune hepatitisKANZLER, Stephan; GERKEN, Guido; LÖHR, Hanns et al.Journal of hepatology. 2001, Vol 34, Num 2, pp 354-355, issn 0168-8278Article

Hepatocellular expression of a dominant-negative mutant TGF-β type II receptor accelerates chemically induced hepatocarcinogenesisKANZLER, Stephan; MEYER, Erik; LOHSE, Ansgar Wilhelm et al.Oncogene (Basingstoke). 2001, Vol 20, Num 36, pp 5015-5024, issn 0950-9232Article

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib TreatmentWÖRNS, Marcus Alexander; SCHUCHMANN, Marcus; DÜBER, Christoph et al.Oncology. 2010, Vol 79, Num 1-2, pp 85-92, issn 0030-2414, 8 p.Article

Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cellsURBANIK, Toni; KÖHLER, Bruno Christian; SCHULZE-BERGKAMEN, Henning et al.International journal of oncology. 2011, Vol 38, Num 1, pp 121-131, issn 1019-6439, 11 p.Article

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver CirrhosisWARNS, Marcus Alexander; WEINMANN, Arndt; OTTO, Gerd et al.Journal of clinical gastroenterology. 2009, Vol 43, Num 5, pp 489-495, issn 0192-0790, 7 p.Article